Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer

Andrew Armstrong • 3 Jun 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer

Andrew Armstrong, MD, MS, Duke University Medical Center, Durham, NC, discusses findings from a retrospective analysis of the PROMISE clinical genomic database evaluating the association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer. Prof. Armstrong highlights links between active smoking and specific genomic alterations, including FGFR1, ARID1A, and SPOP mutations, as well as the significantly higher risk of prostate cancer mortality observed in active smokers. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Armstrong

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
1:16
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
Andrew Armstrong • 26 Feb 2026
Implementing PCWG4 guidance to refine endpoints in prostate cancer
1:23
Implementing PCWG4 guidance to refine endpoints in prostate cancer
Andrew Armstrong • 26 Feb 2026

Related Videos

Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
The content of VJOncology is intended for healthcare professionals